Efficacy and safety of belimumab in IgA nephropathy: real-world evidence
Belimumab treatment was associated with higher proteinuria remission rates in patients with IgAN, without an increased incidence of common adverse events. These findings suggest that belimumab may represent a superior therapeutic approach for IgAN in real-world clinical practice.
Authors
- Xingyang Zhao (ORCID: https://orcid.org/0009-0001-5663-7073)
- Qiang Zhou (ORCID: https://orcid.org/0000-0002-9410-9271)
- Junhua Li (ORCID: https://orcid.org/0000-0002-9611-9801)
- Bowen Qin
- Yichun Cheng (ORCID: https://orcid.org/0009-0009-3062-749X)
- Ge Xu (ORCID: https://orcid.org/0000-0001-9677-8586)
- Qingquan Liu (ORCID: https://orcid.org/0000-0002-0037-290X)
- Xiaojing Cai (ORCID: https://orcid.org/0009-0002-9728-7089)
- Chen Pan (ORCID: https://orcid.org/0000-0002-0347-811X)
- Hairui Zhao
- Xiaoyan Chang
- Han Zhu
- Xiaocheng Liu
- Fang Xiao
- Manyi Wu
- Shuwang Ge
- Hui Zhang
Institutions
- Tongji Hospital (CN)
- Wuhan University of Science and Technology (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2026-03-22
- DOI
- https://doi.org/10.1093/ndt/gfag067
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00